Rocket One Inc. Common Stock (NASDAQ:RKTO) Announces Quarterly Earnings Results

Rocket One Inc. Common Stock (NASDAQ:RKTO – Get Free Report) issued its quarterly earnings results on Friday. The company reported ($0.11) earnings per share for the quarter, FiscalAI reports.

Rocket One Inc. Common Stock Stock Performance

Rocket One Inc. Common Stock stock traded down $0.02 during trading on Friday, reaching $0.32. The company had a trading volume of 219,607 shares, compared to its average volume of 332,302. Rocket One Inc. Common Stock has a 12-month low of $0.32 and a 12-month high of $2.45. The stock’s 50 day moving average price is $0.60 and its two-hundred day moving average price is $0.82. The firm has a market capitalization of $7.99 million, a price-to-earnings ratio of -0.39 and a beta of 1.01.

Hedge Funds Weigh In On Rocket One Inc. Common Stock

A hedge fund recently raised its position in Rocket One Inc. Common Stock stock. Lido Advisors LLC lifted its position in shares of Rocket One Inc. Common Stock (NASDAQ:RKTO – Free Report) by 100.0% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 39,000 shares of the company’s stock after buying an additional 19,500 shares during the period. Lido Advisors LLC owned approximately 0.20% of Rocket One Inc. Common Stock worth $33,000 as of its most recent SEC filing. 7.08% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on RKTO. Weiss Ratings upgraded Rocket One Inc. Common Stock from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, October 29th. Wall Street Zen upgraded Rocket One Inc. Common Stock from a “strong sell” rating to a “sell” rating in a research note on Sunday, October 25th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Rocket One Inc. Common Stock currently has a consensus rating of “Hold” and a consensus target price of $5.00.

View Our Latest Stock Analysis on RKTO

About Rocket One Inc. Common Stock

(Get Free Report)

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.

Read More

Earnings History for Rocket One Inc. Common Stock (NASDAQ:RKTO)

Receive News & Ratings for Rocket One Inc. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket One Inc. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.